Global Biologic Therapies for Wound Care Market
Dublin, June 14, 2022 (GLOBE NEWSWIRE) -- The "Biologic Therapies for Wound Care: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
This report studies the global market for wound care biologics. It describes different types of wound care biologics, including cellular and/or tissue-based products (CTPs), skin substitutes and topical agents, and their current and historical market revenues.
Wound treatment is complex and varies across a broad continuum of care. A significant percentage of hard-to-heal wounds often require a number of advanced solutions. Biological therapies are an emerging approach in modern wound care, as they can stimulate the body's own natural healing power by activating its inherent ability to repair and regenerate.
These utilize some form of biological component such as collagen, cells and ECM technologies to support wound closure. The mechanism of action involves orchestrating an ideal environment to support regenerative healing as well as help stimulate the recruitment and proliferation of cells involved in wound repair.
The overall cost of treating hard-to-heal wounds is rising sharply. Due to the enormous costs associated with delayed wound healing, a growing number of patients worldwide are receiving advanced treatment of wounds. Biologics have demonstrated improved chronic and acute wound healing rates at a lower overall cost than traditional wound care products, and demand for these products is growing. Wound care biologics manufacturers are investing in educating healthcare professionals and clinicians about the clinical and cost advantages of biologics in wound care.
As the global healthcare system moves from a fee-for-service to a value-based health care delivery and reimbursement model, the demand for biologics is expected to grow significantly in coming years. The market is also expected to benefit from continuous R&D. However, high cost, reimbursement and pricing issues and a changing regulatory landscape remain the key restraining factors in the market.
Skin substitutes are categorized into acellular and cellular composition, as well as biologic and bioengineered materials. Biologic skin substitutes are categorized into allografts and acellular animal derived tissue-based products or xenografts. Bioengineered skin substitutes are categorized into cellular and acellular or biosynthetic.
This report also studies applications for biologics in the care of chronic wounds and acute wounds. The market for chronic wounds includes venous leg ulcers, diabetic foot ulcers, pressure ulcers, and arterial and other ulcers. The market for acute wounds includes surgical and traumatic wounds and burns. An in-depth analysis of the market includes historical data and market projections based on sales by product type, application, end user and region.
The report provides discusses the competitive landscape, key competitors and their respective market shares. The scope of this report does not include biologics used for soft tissue reinforcement during plastic and reconstructive surgery. Such surgery is performed to treat structures of the human body that are affected aesthetically or functionally due to defects and abnormalities.
Analyses of the global market trends, with historic revenue (sales) data for 2019-2021, and projections of compound annual growth rates (CAGRs) through 2026
Characterization and quantification of the market potential for wound care biologics, and market size estimation and forecast by product type, composition, application, end user vertical, and geographic region
Description of the integumentary system, wound classifications and wound healing process, and discussion on ECM composition and its importance in skin wound healing
Insight into the recent government regulations, reimbursement procedures, technological updates, 510 (K) approvals, and active clinical trials in wound care biologics that can shape the future marketplace
In-depth information (facts and figures) concerning market drivers, challenges and issues, and other macroeconomic forces influencing the progress of this market
Market share analysis of the key companies operating in the industry and Porter's five forces analysis and their impact on the global market for wound care biologics
Descriptive company profiles of major global players, including AlloSource, Bioventus LLC, BioTissue Inc., Integra LifeSciences Corp., MiMedx, Stryker Corp., and Smith & Nephew, Plc
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Wound Healing Process
Maturation or Remodeling
Ecm Composition and Its Importance in Skin Wound Healing
Biological Therapies for Wound Care
Chapter 4 Market Dynamics
Favorable Global Demographics and Aging Population
Greater Incidence of Non-Communicable/Chronic Diseases
Increasing Acceptance of Regenerative Technologies and Protocols for Complex Wound Treatment
Increasing Technology Innovations and New Product Developments
Improving Reimbursement Environment
Reimbursement and Pricing Issues
Changing Regulatory Landscape
Underpenetrated Markets Outside the U.S.
Impact of Covid-19 on the Global Market for Wound Biologics
Chapter 5 Market Breakdown by Technology Type
Ctps or Skin Substitutes
Global Market for Wound Biologics by Product Type
Ctps or Skin Substitute Types
Global Market for Ctps/Skin Substitutes, by Composition Type
Based on Type of Material
Biologic Skin Substitutes/Biologic Grafts
Bioengineered Skin Substitutes/Bioengineered Grafts
Global Market for Ctps/Skin Substitutes by Material
Global Market for Biologic Ctps/Skin Substitutes by Tissue Source
Global Market for Bioengineered Skin Substitutes by Composition Type
Chapter 6 Market Breakdown by Application
Common Types of Chronic Wounds
Common Types of Acute Wounds
Global Market for Wound Care Biologics by Wound Type
Global Market for Chronic Wound Care Biologics by Wound Type
Global Market for Acute Wound Care Biologics by Wound Type
Chapter 7 Market Breakdown by Region
Global Market for Wound Care Biologics by Region
Rest of World
Chapter 8 Market Breakdown by End-user
Hospital Outpatient Wound Centers
Office or Clinic Settings
Global Market for Wound Care Biologics by End-user
Chapter 9 Regulatory Structure and New Product Developments
Fda Regulatory Review and Approval Process Governing Ctps or Skin Substitutes
Biologics License Application
361 Human Cells, Tissues and Cellular and Tissue-Based Products (Hct/Ps)
Humanitarian Device Exemption
Coverage and Reimbursement
Fda Approvals for Wound Care Biologics by Approval Type
510 (K) Approvals
Wound Care Biologics in Clinical Development
Chapter 10 Competitive Landscape
Market Shares of Leading Companies
Key Market Players by Product Type
Acellular Animal Derived Tissue-Based Products/Xenografts
Porter's Five Forces Analysis
Chapter 11 Company Profiles
Aroa Biosurgery Ltd.
Convatec Group plc
Cook Biotech Inc.
Integra Lifesciences Holdings Corp.
Organogenesis Holdings Inc.
Skye Biologics Holdings, LLC
Smith & Nephew, plc
Zimmer Biomet Holdings Inc.
For more information about this report visit https://www.researchandmarkets.com/r/kr1oz8
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900